Break the cycle for ADHD patients 6 years and older[1]

INDICATION

Qelbree is indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in pediatric and adult patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

Please see full Important Safety Information on page 3.

ONCE-DAILY Qelbree® viloxazine extended-release capsules 100 mg 150 mg 200 mg

Abbreviation: ADHD, attention-deficit/hyperactivity disorder.

Break the cycle for ADHD patients 6 years and older[1]...

Choose 24-hour coverage and dosing versatility[1,2]

Qelbree is prescribed once daily (AM or PM) for full 24-hour exposure[1,2]

Titrate weekly as needed to optimize ADHD symptom control[1]

Children 6 to 11 Years[1]

Titrate Qelbree 100 mg/week over 1 to 3 weeks **as needed to reach effective dose[1]**

Week 1	Week 2	Week 3	Week 4
SPN 100	SPN 200	SPN 150 + SPN 150	SPN 200 + SPN 200
100 mg QD (starting dose)	200 mg QD	300 mg QD	400 mg QD

Maximum dose 400 mg/day[1]: SPN 200 + SPN 200

Teens 12 to 17 Years[1]

Titrate Qelbree 200 mg/week over 1 week **as needed to reach effective dose[1]**

Week 1	Week 2
SPN 200	SPN 200 + SPN 200
200 mg QD (starting dose)	400 mg QD

Maximum dose 400 mg/day[1]: SPN 200 + SPN 200

Adults 18 to 65 Years[1]

Titrate Qelbree 200 mg/week over 1 to 2 weeks **as needed to reach effective dose[1]**

Week 1	Week 2	Week 3
SPN 200	SPN 200 + SPN 200	SPN 200 + SPN 200 + SPN 200
200 mg QD (starting dose)	400 mg QD	600 mg QD

Maximum dose 600 mg/day[1]: SPN 200 + SPN 200 + SPN 200

Capsules shown are not actual size.

90 days of treatment with **1 co-pay***

Patients pay as little as $20 per month!*

*Terms and conditions apply.

Choose straightforward, convenient dosing administration and titration[1]

Administration[1]

Capsule can be taken whole, or entire contents can be sprinkled over a spoonful of soft food (pudding or applesauce). Consume the mixture in its entirety, without chewing, within 15 minutes for pudding or within 2 hours for applesauce; do not store for future use.

- Capsules and their contents should not be cut, crushed, or chewed[1]
- Can be taken with or without food[1]

Capsule

Sprinkled on pudding or applesauce*

Capsules shown are not actual size.

*Dose will depend on response to medication.

Qelbree can be conveniently prescribed and refilled without a new prescription every month—for up to 90 days of treatment in 1 Rx.[2]

Qelbree has no known addiction potential or evidence of abuse.[1,3,4]

IMPORTANT SAFETY INFORMATION

- *Severe renal impairment*: Initiate Qelbree at 100 mg once daily and increase by 50 mg to 100 mg at weekly intervals to a maximum recommended dosage of 200 mg once daily
- *Heart rate, blood pressure increases*: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy

Please see full Important Safety Information on page 3.

ONCE-DAILY Qelbree® viloxazine extended-release capsules 100 mg 150 mg 200 mg

INDICATION

Qelbree® (viloxazine extended-release capsules) is indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS

- Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
- Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

- *Suicidal thoughts and behaviors*: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
- *Heart rate, blood pressure increases*: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
- *Activation of mania or hypomania*: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression

WARNINGS & PRECAUTIONS (CONT'D)

- *Somnolence and fatigue*: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation.

PREGNANCY & LACTATION

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg.

Please see full Prescribing Information, including Boxed Warning.

REFERENCES: 1. Qelbree [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc. **2.** Data on file, Supernus Pharmaceuticals, Inc. **3.** Yanagita T, Wakasa Y, Kiyohara H. Drug dependence potential of viloxazine hydrochloride tested in rhesus monkeys. *Pharmacol Biochem Behav*. 1980;12(1):155-161. **4.** U.S. Food and Drug Administration. Qelbree (viloxazine) - NDA 211964. Drugs@FDA. Updated April 29, 2022. Accessed March 17, 2026. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211964